The Extended Salford Lung Study (“Ex-SLS”) Data Access Project


The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period. Subjects in the SLS originally consented for information relevant to the study to be shared with the sponsor (GSK). These data were limited to three years prior to randomisation and the twelve-month interventional treatment period. Broadened access to patients' data would allow SLS subjects' entire disease journey to be researched, presenting a rare opportunity to improve scientific and clinical understanding of COPD/asthma disease risk, treatment and progression. This proposal seeks to collect additional subject-level data from SLS patients via their electronic medical records (encompassing past and future data for up to 10 years from the date of consent) and via a one-off patient questionnaire administered at the time of consent.

Full Title of Study: “The Extended Salford Lung Study (“Ex-SLS”) Data Access Project”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: April 30, 2028

Arms, Groups and Cohorts

  • Chronic obstructive pulmonary disease
    • Subjects with COPD who were randomised to treatment in the original SLS
  • Asthma
    • Subjects with asthma who were randomised to treatment in the original SLS.

Clinical Trial Outcome Measures

Primary Measures

  • Retrospective EMR data
    • Time Frame: Up to 10 years
    • All historical data from consent until the beginning of patients’ electronic health records, encompassing all routinely-available electronic demographic and health-related data back to a patients’ earliest available electronic record.
  • Prospective EMR data
    • Time Frame: Up to 10 years
    • Prospective longitudinal data, encompassing collection of future routinely-recorded electronic demographic and health-related data for a period of ten years from this consent or until a patient is either lost to follow up or at the time of their death.
  • Risk factor questionnaire
    • Time Frame: Up to 10 years
    • Historical demographic, COPD/asthma risk factor information and clinical data not routinely available. Collected via paper questionnaire.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects who were randomized to treatment in the original SLS studies – Subjects who are able to, and choose to, provide written consent for the additional information to be collected. Exclusion Criteria:

  • Subjects who were lost to follow-up/moved away, withdrew consent or died during or subsequent to the original SLS studies. – Subjects considered (at the discretion of the investigator) as too ill to participate or without the mental capacity to provide informed consent.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, GlaxoSmithKline

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.